https://www.selleckchem.com/pr....oducts/pqr309-bimira
This study assessed pharmacoeconomic costs associated with extracorporeal photopheresis (ECP) compared with other available second-line therapies for chronic graft-vs-host disease (cGvHD) in a tertiary Spanish institution. Patients (≥18 years) diagnosed with steroid-refractory cGvHD were eligible. Data were collected retrospectively from index date until 1year or relapse. Patients were distributed in two cohorts (ECP vs non-ECP), matched by age (≤ or 4, hematopoietic stem cell transplant (HLA-identical sibling donor or
Suka
Komentar
Membagikan
